Term
| Contemporary Psychopharmacological Care |
|
Definition
Based on:
mental health recovery
adherence to medication
Pubic Health Ads
huge change from the 1950s |
|
|
Term
|
Definition
need to know whether they're taking their meds or not, why not, since when, if not the full dose, then how much, etc.
be very specific |
|
|
Term
| Psychopharmacological Assessment |
|
Definition
3 things:
past meds
adherence
side effects |
|
|
Term
| common obstacle to the planning phase of the nursing process when it comes to psychopharmacology |
|
Definition
knowledge deficit r/t medications
the population of people with MHCs are disproportionately un-/undereducated, and some MHCs also cause learning disabilities |
|
|
Term
| Oral Liquid (Concentrate) Administration: examples in psychopharm, and potential drawback |
|
Definition
Prozac, lithium
difficult to measure interactions w/ other liquids |
|
|
Term
|
Definition
medication administration method more often used in MH than other specialties: monthly IM injection which slowly releases medication over time
Ethics: these can't be given against patient consent like some emergent medications can |
|
|
Term
| Psychopharm considerations r/t young people |
|
Definition
Danger: most MHC meds are tested on adults, so new meds--if given--should be monitored closely
Stigma: negative outlook on "crazy kids," from friends, friends' parents, and even themselves
Education: about available interventions, and psychological needs |
|
|
Term
| Pschyopharm considerations r/t older people |
|
Definition
| Due to varying effects of aging, as well as wide range of other meds (not to mention non-adherence/non-report to/of those meds), older pts are at a higher risk for unforeseen side-effects, and should therefore be started on low doses, slowly increasing them to find the best therapeutic effect for the minimum side-effects |
|
|
Term
|
Definition
| drug/agent that binds the post-synaptic receptor and activates the related pathway |
|
|
Term
|
Definition
| drug/agent that binds the post-synaptic receptor and does not activate the related pathway, thereby blocking its activation via that receptor |
|
|
Term
|
Definition
| binds presynaptic receptor to no effect, thereby allowing the neurotransmitter more time in the synapse to activate more receptors |
|
|
Term
A Pt being treated for stress-related HTN presents with hypotension, dizziness, tachycardia, and ED.
What is likely the cause? |
|
Definition
|
|
Term
A pt being treated for psychosis presents with hypotension and ED.
What is likely the cause? |
|
Definition
| 5-HT2 (serotonin) antagonist medication |
|
|
Term
A pt being treated for psychosis presents with akathesia and concentrated urine.
What is likely the cause? |
|
Definition
| D2 (dopamine) antagonist medication |
|
|
Term
A pt being treated for schizophrenia is sedated, drowsy, and hypotensive. Also their weight is significantly higher than the previous week.
What is likely the cause? |
|
Definition
| Histamine (H1) antagonist medication |
|
|
Term
| A pt being treated for Parkinson's presents with dry mouth, constipation, urinary retention, and blurred vision. The likely cause is... |
|
Definition
| ...ACh antagonist medication (specifically muscarinic antagonist medication) |
|
|
Term
a pt being treated for depression is displaying more and more of a disconnect with reality.
The likely cause is... |
|
Definition
| Dopamine reuptake inhibitor (DRI) |
|
|
Term
A pt is being treated for anxiety and depression and presents with upset stomach, nausea, and headache.
The likely cause is... |
|
Definition
| Serotonin-specific reuptake inhibitor (SSRI) |
|
|
Term
a pt being treated for depression presents with tachycardia, tremor, restlessness, and ED.
The likely cause is... |
|
Definition
| Norepinephrine reuptake inhibitor (NRI) |
|
|
Term
| Tricyclic antidepressant MOAs |
|
Definition
5HT: inhibits reuptake
NE: inhibits reuptake, blocks receptor
ACh: blocks receptor
H1: blocks receptor
3-4-5
TRIcyclics act on FOUR molecule-pathways having FIVE total effects |
|
|
Term
|
Definition
Monoamine Oxidase Inhibitors
antidepressants which block the enzymatic digestion of norepinephrine and serotonin |
|
|
